Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439179 · ClinicalTrials.gov registry record · Phase 1
A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
A Phase 1 study of Metastatic Pancreatic Cancer, sponsored by Brown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT00439179: Completed Phase 1 study of Metastatic Pancreatic Cancer, sponsored by Brown University.
NCT00439179 is a Phase 1 study of Metastatic Pancreatic Cancer that has completed, run by Brown University. The registered enrollment target is 27 participants, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00439179, a Phase 1 study of Metastatic Pancreatic Cancer, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
Primary Outcome
To determine the safety and tolerability of GW572016 when administered with gemcitabine and the combination of gemcitabine and oxaliplatin in patients with advanced pancreaticobiliary cancers. Numbers below are DLTs
Conditions Studied
Interventions
- DRUG cohort 1
- DRUG cohort 2
- DRUG cohort 3
- DRUG cohort 4
Study Locations (1)
Rhode Island
- Brown University Oncology Research Group - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
What the finished NCT00439179 record still lists
NCT00439179 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which cohort 1 is the first listed.
NCT00439179 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT00439179 about?
NCT00439179 is a clinical study titled "A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema". A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
What is the current status of trial NCT00439179?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2006-07. Estimated completion is 2007-12.
What conditions does trial NCT00439179 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Cancer.
What interventions are being tested in trial NCT00439179?
The interventions under investigation include: cohort 1 (DRUG), cohort 2 (DRUG), cohort 3 (DRUG), cohort 4 (DRUG).
Who is sponsoring clinical trial NCT00439179?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00439179 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00439179's enrollment target sits among peer trials
27 26th of 32 higher than 6 of 32 other Metastatic Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
RECRUITING · Phase 1
-
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
RECRUITING · Phase 1
-
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia